----item----
version: 1
id: {BCF61A53-1D19-4A43-8281-81A7AD9882D6}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/31/PharmAsia News business bulletin
parent: {41EBBC65-C73D-4320-B22C-6EBD0BE8A7D8}
name: PharmAsia News business bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: a7ba883f-4062-423d-92d9-de70d76ddec4

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 233

{864F8DF2-858F-4FE1-9E65-EFCEEBFA8288}|{38CC267C-7BFB-437D-BEA0-27DBA7B77873}|{3FA7743D-5DAB-49A3-B30D-DF5079ADB082}|{29C8E5B9-B01E-4DEE-A123-14D70756095B}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}|{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News business bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News business bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 6835

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/3/sanofi-hit-by-plavix-generics-in-japan-but-china-solid" target="_new">Sanofi Hit By Plavix Generics In Japan, But China Solid</a></p><p>During its second quarter earnings announcement, Sanofi talked in detail about the outlook for its Japanese business, which is set to be affected by generic competition to blockbuster Plavix, and also explained its recently announced global business reorganization plan.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/3/astrazeneca-not-immune-to-expected-china-slowdown" target="_new">AstraZeneca Not Immune To &lsquo;Expected&rsquo; China Slowdown</a></p><p>Like a number of other pharma multinationals, AstraZeneca's sales growth in China slowed in the second quarter, but the UK-based firm says this was expected and that it still foresees a double digit increase in the country over the rest of the year.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/5/gsk-resets-china-strategy-with-voluntary-price-cuts" target="_new">GSK Resets China Strategy With Voluntary Price Cuts</a></p><p>Multinational drug companies in the past have generally been highly cautious about lowering prices for fear of triggering a chain reaction and downward spiral. A rare move by GSK in China highlights a dilemma facing such firms as their growth in this market slows significantly &ndash; should you exchange price reductions for volume growth or maintain current policies?</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/6/avastin-lung-cancer-launch-to-bolster-roches-china-sales" target="_new">Avastin Lung Cancer Launch To Bolster Roche's China Sales</a></p><p>Roche has launched Avastin for lung cancer in China, marking the expanded use of one of the company's best-selling therapies globally to treat a prevalent cancer type in the country, where new product approvals have been few and far between.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/7/china-factors-weigh-on-novo-nordisks-q2" target="_new">China Factors Weigh On Novo Nordisk's Q2</a></p><p>It seems there are few big pharma escapees from the growth slowdown in China in the second quarter, with diabetes specialist Novo Nordisk becoming the latest firm to report a mix of increasing challenges in this major emerging market.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/7/medipost-moves-as-cord-blood-bank-controversy-heightens" target="_new">Medipost Moves As Cord Blood Bank Controversy Heightens</a></p><p>As public criticism rises amid recent claims by civic groups that the family cord blood bank business in South Korea is a scam and the government is overlooking the matter, the country's largest such bank has moved to deal with the situation, denying the claims and vowing to strongly act against those who spread such false information, while the government seeks policies to boost donated cord blood.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/6/sorrento-taps-chinas-mabtech-for-biosimilars-deal" target="_new">Sorrento Taps China's Mabtech For Biosimilars Deal</a></p><p>Sorrento Therapeutics has gained exclusive licensing rights from China's Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China's homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/6/indian-pharma-needs-to-catch-up-in-digital-health" target="_new">Indian Pharma Needs To Catch Up In Digital Health</a></p><p>Indian pharmaceutical companies must move much more aggressively to exploit the internet economy and reach out to health practitioners and customers. Technological change is transforming the face of the pharmaceutical industry globally by delivering new web-enabled answers to solve business and healthcare issues, but India's drug sector has fallen badly behind, says a new study.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/5/hanmis-licensing-success-driven-by-strong-clinical-strategy" target="_new">Hanmi's Licensing Success Driven By Strong Clinical Strategy</a></p><p>Hanmi Pharm's recent record license agreements with multinational pharma giants clearly show that the company may be a step or two ahead of its South Korean rivals in R&D and also indicate its strength in oncology. A local brokerage notes its clinical development strategy may also have played a role in this success and suggests ways other domestic pharmas can reduce failures.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/4/zai-builds-on-sanofi-ties-for-lung-cancer-candidate" target="_new">ZAI Builds On Sanofi Ties For Lung Cancer Candidate</a></p><p>China's ZAI Lab has licensed its third preclinical drug candidate from Sanofi, a novel multi-kinase inhibitor aimed at a non-small cell lung cancer target and other oncology indications. The new agreement indicates ZAI's R&D strategy of bringing in novel early stage assets with large unmet needs in China and globally.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/3/more-companies-tapping-direct-sales-route-in-china" target="_new">More Companies Tapping Direct Sales Route In China</a></p><p>Under the influence of a changing policy environment, China's healthcare companies are experiencing a development bottleneck. The need to upgrade to new business models and finding new ways of doing so have become realities for many companies, and more and more are tapping into the opportunities presented by direct sales, including A-share market-listed and state-owned companies.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/8/2/korean-firms-unveil-cell-therapy-progress" target="_new">Korean Firms Unveil Cell Therapy Progress</a></p><p>The latest announcements by Medipost and JW CreaGene in South Korea, where stem cell-based therapy products have been launched for the first time in the world, indicate the country continues to see positive developments in this space.</p><p><p><a href="http://www.pharmasianews.com" target="_new">www.pharmasianews.com</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 249

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>&rsquo;s sister publication <i>PharmAsia News</i>, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News business bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150731T210000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150731T210000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150731T210000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029453
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News business bulletin
----field----
field: {53288D3D-66D7-4ACE-B3E4-D7D02B1F3672}
name: Referenced Companies
key: referenced companies
content-length: 9

199902039
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359731
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042433Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

a7ba883f-4062-423d-92d9-de70d76ddec4
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042433Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
